Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Oct 29, 2021 8:57am
109 Views
Post# 34062411

RE:RE:RE:Steven Harrison

RE:RE:RE:Steven HarrisonYou are putting this in a more proper context probably.  And I think that's right.  He is all over the  industry. I'm totally in the same camp as you -- deals take a lot of time and it is definitely born of pragmatism. The FDA sort of forced pragmatism into the equation and adding that interim read is a solid add-on in my view. I still think there's the Plan 1A -hiring the bankers to narrow down serious partners, and a Plan 1B -prove TH1902 POC, move ahead and hope share reflects the new path of this potentially valuable pipeline asset, raise $100mil north of $10 and be on your way.

qwerty22 wrote:

I was just thinking it's a difficult space to do a deal in, you went a whole lot darker. Just to try bringing it back toward the light. Harrison has his fingers in many, many pies. I expect it's a more general impression of the situation rather than thtx specifically. I think you and me think the deal making process takes longer. If thtx are having any success than it's probably still early/mid stage. If that was the case then I don't think that would make much impression on Harrison's overall opinion of the state of deal making in NASH. Still definitely an uphill struggle. To be honest I've always thought THTX's 'decision' to look for a partner was driven by pragmatism. More just a recognition that something needs to change before they can activate the program. 

 

Wino115 wrote: Putting 2+2 together, Harrison was just talking with THTX management about their program and has been hired as a KOL/Advisor or something and he very clearly states in the podcast that money pursuing NASH is on the sidelines right now until a success is seen.  This leads to the inevitable conclusion that  some of Harrison's opinion is informed by tidbits he may have picked up  around the THTX NASH partnering process.  Pure speculation, but I'm pretty sure he would not have said that if he had heard there were multiple ongoing discussions that happened quickly from Paul. 
 

 

qwerty22 wrote: Fairly sobering assessment of the state of NASH drug development landscape from SH. Start at 42:10. You have to remember this is a guy whose professional career(his business, his clinical and academic career) is completely focused around success in the NASH space.

https://surfingnash.com/s2-e51-precision-medicine-fibrosis-liver-function-and-the-future-a-discussion-with-scott-friedman/

The need for a company to get a win in the NASH space and to get beyond biopsy seem like bigger factors than the internal merits of any program.

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse